Physician profile
Anna Kula
NPI 1346420197
$2,748.23
in general payments reported to CMS, 2019-2025
14 companies · $24.15 in 2025
The $24.15 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,186 · 2022: $1,195 · 2023: $312 · 2024: $30.54 · 2025: $24.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,640.88 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $307.95 | 2021-2023 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $166.27 | 2023-2025 | Trogarzo, Egrifta |
| Viiv Healthcare Company | $133.96 | 2021-2022 | |
| Gilead Sciences, INC. | $113.82 | 2021-2022 | |
| Abbvie INC. | $93.34 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $69.39 | 2022-2023 | |
| Melinta Therapeutics, LLC | $50.54 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $49.67 | 2021-2023 | Vibativ |
| Shionogi INC | $38.61 | 2021 | |
| Pfizer INC. | $24.88 | 2021 | |
| Daiichi Sankyo INC. | $24.62 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.